Organon & Co. (OGN)

$6.34 -0.01 (-0.16%)
Market Cap 1.65B
Revenue (ttm) 6.22B
Net Income (ttm) 187.00M
EPS (ttm) N/A
PE Ratio 1.85
Forward PE 1.96
Profit Margin 3.01%
Debt to Equity Ratio 11.49
Volume 3,536,122
Avg Vol 5,235,664
Day's Range N/A - N/A
Shares Out 260.32M
Stochastic %K 9%
Beta 0.60
Analysts Hold
Price Target $9.57

Company Profile

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551-430-6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
Boss2023
Boss2023 Mar. 8 at 10:57 PM
$OGN now would be a good time to announce the Sun buyout. Market is going to tank tomorrow, this along with everything but shorts and oil.
0 · Reply
Rufusbird
Rufusbird Mar. 5 at 2:59 PM
$OGN Hold on to your hats, shorts, the ride is going to get a little bumpy from here...: ) Long and strong!
1 · Reply
AndyJo
AndyJo Mar. 3 at 12:29 PM
$OGN dont forget it: https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-places-non-binding-offer-for-us-based-organon-in-its-boldest-global-bet-ever/amp_articleshow/126714515.cms
2 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 7:15 PM
$OGN just added a new angle to its dermatology push 👀 Phase 3 data show VTAMA improved sleep in children as young as two with atopic dermatitis — a meaningful benefit beyond just skin clearance. That strengthens the product’s profile in a competitive space. Is this the kind of differentiation that moves the needle for Organon? Deep dive here 👉 https://www.zacks.com/stock/news/2877733/ogns-vtama-cream-shows-sleep-benefits-in-pediatric-atopic-dermatitis?cid=sm-stocktwits-2-2877733-teaser-35804&ADID=SYND_STOCKTWITS_TWEET_2_2877733_TEASER_35804
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 6:15 PM
$OGN gains 0.8% on promising VTAMA trial data, marking a small recovery from a 22.6% decline in 6 months. 🤔 👶 Positive sleep outcome improvements in pediatric AD patients 🌟 Strong efficacy across age groups with prior FDA approvals Discover the full story behind the stock's recent move 👉 https://www.zacks.com/stock/news/2877733/ogns-vtama-cream-shows-sleep-benefits-in-pediatric-atopic-dermatitis?cid=sm-stocktwits-2-2877733-body-35794&ADID=SYND_STOCKTWITS_TWEET_2_2877733_BODY_35794
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 1:02 PM
$OGN Organon will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, A…
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 6:46 PM
$OGN is showing defensive resilience. While 1D STOCH is overbought at 84, the 1W timeframe holds support. High 4H and 30M volatility suggests range-bound price action until the 1D indicators reset to neutral. @DailyAnalysis
0 · Reply
erevnon
erevnon Feb. 24 at 3:12 PM
Barclays maintains Organon $OGN at Underweight and raises the price target from $7.5 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Feb. 24 at 6:10 AM
$OGN is expanding its women's health pipeline with exclusive global rights to MIUDELLA from Sebela Pharma. This is the first new hormone-free copper IUD approved in the US in 40 years. The terms: $27.5M upfront, up to $505 M in potential milestones, and double-digit royalties. With FDA approval already secured last year, commercial launch is pending supply chain clearance. A solid, strategic addition to their existing contraceptive portfolio.
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 6:56 PM
$OGN is showing defensive resilience. While 1D STOCH is overbought at 84, the 1W timeframe holds support. High 4H and 30M volatility suggests range-bound price action until the 1D indicators reset to neutral. @DailyAnalysis
0 · Reply
Latest News on OGN
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

Mar 3, 2026, 4:49 AM EST - 13 days ago

KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Feb 27, 2026, 8:00 AM EST - 17 days ago

New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Feb 23, 2026, 7:30 AM EST - 21 days ago

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty

Feb 22, 2026, 4:56 AM EST - 22 days ago

Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty

Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off

Feb 12, 2026, 12:43 PM EST - 4 weeks ago

Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off

Organon & Co. (OGN) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 10:44 AM EST - 4 weeks ago

Organon & Co. (OGN) Q4 2025 Earnings Call Transcript

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Feb 12, 2026, 7:30 AM EST - 4 weeks ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Jan 29, 2026, 7:30 AM EST - 6 weeks ago

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Organon Completes Divestiture of JADA® System to Laborie

Jan 28, 2026, 12:45 PM EST - 6 weeks ago

Organon Completes Divestiture of JADA® System to Laborie

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Jan 20, 2026, 10:31 AM EST - 7 weeks ago

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Jan 16, 2026, 9:12 PM EST - 2 months ago

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Jan 8, 2026, 1:30 AM EST - 2 months ago

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 12:23 PM EST - 3 months ago

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 3 months ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 17, 2025, 5:30 AM EST - 4 months ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Nov 11, 2025, 12:58 PM EST - 4 months ago

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Organon Analysts Cut Their Forecasts Following Q3 Results

Nov 11, 2025, 11:40 AM EST - 4 months ago

Organon Analysts Cut Their Forecasts Following Q3 Results

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:51 AM EST - 4 months ago

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 10, 2025, 7:30 AM EST - 4 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 7, 2025, 7:30 AM EST - 4 months ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Nov 6, 2025, 7:30 AM EST - 4 months ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Oct 28, 2025, 2:06 PM EDT - 4 months ago

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Oct 27, 2025, 6:22 PM EDT - 5 months ago

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:44 AM EDT - 5 months ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 27, 2025, 7:30 AM EDT - 5 months ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Oct 17, 2025, 7:10 AM EDT - 5 months ago

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 19, 2025, 6:00 AM EDT - 6 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 6 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon: Valuation Discount Offset By Structural Headwinds

Aug 12, 2025, 2:22 PM EDT - 7 months ago

Organon: Valuation Discount Offset By Structural Headwinds

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 6, 2025, 11:59 AM EDT - 7 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:10 PM EDT - 7 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Organon Reports Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 7:30 AM EDT - 7 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 22, 2025, 7:30 AM EDT - 8 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 21, 2025, 4:02 PM EDT - 8 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 20, 2025, 10:55 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 8 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 8 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 7, 2025, 7:30 AM EDT - 9 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 8:25 AM EDT - 9 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Karolinska Development receives update from Organon concerning OG-6219

Jul 3, 2025, 1:00 AM EDT - 9 months ago

Karolinska Development receives update from Organon concerning OG-6219

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 8:01 AM EDT - 9 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jul 2, 2025, 7:30 AM EDT - 9 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Boss2023
Boss2023 Mar. 8 at 10:57 PM
$OGN now would be a good time to announce the Sun buyout. Market is going to tank tomorrow, this along with everything but shorts and oil.
0 · Reply
Rufusbird
Rufusbird Mar. 5 at 2:59 PM
$OGN Hold on to your hats, shorts, the ride is going to get a little bumpy from here...: ) Long and strong!
1 · Reply
AndyJo
AndyJo Mar. 3 at 12:29 PM
$OGN dont forget it: https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-places-non-binding-offer-for-us-based-organon-in-its-boldest-global-bet-ever/amp_articleshow/126714515.cms
2 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 7:15 PM
$OGN just added a new angle to its dermatology push 👀 Phase 3 data show VTAMA improved sleep in children as young as two with atopic dermatitis — a meaningful benefit beyond just skin clearance. That strengthens the product’s profile in a competitive space. Is this the kind of differentiation that moves the needle for Organon? Deep dive here 👉 https://www.zacks.com/stock/news/2877733/ogns-vtama-cream-shows-sleep-benefits-in-pediatric-atopic-dermatitis?cid=sm-stocktwits-2-2877733-teaser-35804&ADID=SYND_STOCKTWITS_TWEET_2_2877733_TEASER_35804
0 · Reply
ZacksResearch
ZacksResearch Mar. 2 at 6:15 PM
$OGN gains 0.8% on promising VTAMA trial data, marking a small recovery from a 22.6% decline in 6 months. 🤔 👶 Positive sleep outcome improvements in pediatric AD patients 🌟 Strong efficacy across age groups with prior FDA approvals Discover the full story behind the stock's recent move 👉 https://www.zacks.com/stock/news/2877733/ogns-vtama-cream-shows-sleep-benefits-in-pediatric-atopic-dermatitis?cid=sm-stocktwits-2-2877733-body-35794&ADID=SYND_STOCKTWITS_TWEET_2_2877733_BODY_35794
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 1:02 PM
$OGN Organon will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, A…
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 6:46 PM
$OGN is showing defensive resilience. While 1D STOCH is overbought at 84, the 1W timeframe holds support. High 4H and 30M volatility suggests range-bound price action until the 1D indicators reset to neutral. @DailyAnalysis
0 · Reply
erevnon
erevnon Feb. 24 at 3:12 PM
Barclays maintains Organon $OGN at Underweight and raises the price target from $7.5 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Feb. 24 at 6:10 AM
$OGN is expanding its women's health pipeline with exclusive global rights to MIUDELLA from Sebela Pharma. This is the first new hormone-free copper IUD approved in the US in 40 years. The terms: $27.5M upfront, up to $505 M in potential milestones, and double-digit royalties. With FDA approval already secured last year, commercial launch is pending supply chain clearance. A solid, strategic addition to their existing contraceptive portfolio.
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 6:56 PM
$OGN is showing defensive resilience. While 1D STOCH is overbought at 84, the 1W timeframe holds support. High 4H and 30M volatility suggests range-bound price action until the 1D indicators reset to neutral. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 22 at 5:13 PM
$OGN is showing defensive resilience. While 1D STOCH is overbought at 84, the 1W timeframe holds support. High 4H and 30M volatility suggests range-bound price action until the 1D indicators reset to neutral. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 21 at 8:40 PM
$OGN is bouncing, but 1D STOCH and CCI are already looking stretched. 4H RSI is high while 1W remains in a downtrend. 30M stability is key to see if this rally is real. @DailyAnalysis
0 · Reply
handmedown1
handmedown1 Feb. 20 at 4:43 PM
$OGN so it was a nothing burger???
0 · Reply
topstockalerts
topstockalerts Feb. 20 at 1:53 PM
Organon & Co. said its audit committee has completed an independent review into prior-year biosimilar purchases from a supplier and found no evidence of misconduct. According to an SEC filing, the review was conducted with the assistance of external legal advisers and concluded that no action is required. The company added that the investigation did not identify any issues requiring restatements of previously issued financial statements or amendments to past SEC disclosures. The audit committee launched the review on Feb. 11 after information was brought to its attention regarding the timing of certain biosimilar purchases in prior years. Organon publicly disclosed the review on Feb. 12. The company said it expects to file its Form 10-K for the year ended Dec. 31, 2025, on time. $OGN
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Feb. 20 at 1:51 PM
$OGN 💊 1 Hour Levels Price: $7.90 Support: $7.50 Resistance: $8.40 👉 Tap follow to keep these 1-hour levels on your feed.
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 20 at 1:27 PM
$OGN (+5.7% pre) Organon audit committee finds no improper conduct in biosimilar purchases - SI https://ooc.bz/l/94031
0 · Reply
handmedown1
handmedown1 Feb. 20 at 12:42 PM
$OGN news??
0 · Reply
AndyJo
AndyJo Feb. 14 at 8:26 AM
$OGN If Sun Pharma acquires the company for $10 billion, we would have an offer price of $7.40 per share, net of debt.
1 · Reply
c0ffee
c0ffee Feb. 13 at 12:58 PM
$OGN hopefully the biosimilar inquiry is resolved in the next few months so interested companies can pursue a buyout again. I am assuming that with the revenue and cash flow, a buyout, if it happens, would likely be at least $12B ($13/sh after debt ), and if OGN is able to hire a CEO with industry pedigree, along with multiple bids, could reach $14B ($22/sh after debt).
0 · Reply
handmedown1
handmedown1 Feb. 12 at 2:53 PM
$OGN any questions on a buyout?
0 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Feb. 12 at 2:36 PM
$OGN classic earnings dump
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 12 at 12:53 PM
$OGN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.79 down -288.10% YoY • Reported revenue of $1.51B down -5.34% YoY • For full year 2026, Organon expects to achieve revenue of approximately $6.2B and Adjusted EBITDA of approximately $1.9B, both measures in-line with 2025 performance.
0 · Reply